BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group

Journal of Clinical Oncology

Volumn 16, Issue 12, 1998, Pages 3810-3821

  Diehl, Volker ^a   Franklin, Jeremy ^a   Hasenclever, Dirk ^a   Tesch, Hans ^a   Pfreundschuh, Michael ^a   Lathan, Bernd ^a   Paulus, Ursula ^a   Sieber, Markus ^a   Rueffer, Jens Ulrich ^a   Sextro, Michael ^a   Engert, Andreas ^a   Wolf, Juergen ^a   Hermann, Richard ^a   Holmer, Lars ^a   Stappert Jahn, Ulrike ^a   Winnerlein Trump, Eva ^a   Wulf, Gerald ^a   Krause, Stefan ^a   Glunz, Axel ^a   Von Kalle, Katrin ^a   Bischoff, Helge ^a   Haedicke, Christoph ^a   Duehmke, Eckert ^a   Georgii, Axel ^a   Loeffler, Markus ^a   more..

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFECTIOUS COMPLICATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032422646     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.12.3810     Document Type: Article

References (38)

1. De Vita VT, Simon RM, Hubbard SM, et al: Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92:587-595, 1980
2. Bonadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin's disease with doxorubicin, bleomycin. vinblastine and imidazole carboximide versus MOPP. Cancer 36:252-259, 1975
3. Somers R, Henry-Amar M, Meerwaldt JK, et al (eds): Treatment Strategy in Hodgkin's Disease. Institut National de Lra Santé et de la Recherche Medicale Colloquium. London, England. Libbey. 1990. pp 169-418
4. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP. ABVD or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
5. Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy - Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:1638-1645, 1997
6. Viviani S, Bonadonna G, Santoro A, et al: Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 14:1421-1430, 1996
7. Hancock BW, Vaughan-Hudson G, Vaughan-Hudson B, et al: Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: A prematurely terminated British National Lymphoma Investigation randomized trial. Ann Oncol 5:117-120, 1994 (suppl 2)
8. th Annual Meeting. Blood 90:586a, 1997 (abstr 2605)
9. De Vita VT Jr, Hubbard SM, Longo DL: The chemotherapy of Hodgkin's disease: Looking back, moving forward - The Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 47:5810-5824. 1987
10. Linch DC: Dose optimisation and dose intensification in malignant lymphoma. Eur J Cancer 30A: 122-125, 1994
11. Gerhartz HH, Schwenke H, Bazarbashis, et al: Randomised comparison of COPP/ABVD versus dose-and time-escalated COPP/ ABVD with GM-CSF support for advanced Hodgkin's disease. Proc ASCO 16:8a, 1997 (abstr 25)
12. Loeffler M, Dixon DO, Swindell R: Prognostic factors of stage III and IV Hodgkin's disease, in Sommers R. Henry-Amar M, Meerwaldt JK, et al (eds): Treatment Strategy in Hodgkin's Disease. INSERM Colloquium. London, England, Libbey, 1990, pp 89-102
13. Hasenclever D, Schmitz N, Diehl V: Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease. German Hodgkin's Study Group. Ann Oncol 7:95-98, 1996 (suppl 4)
14. Frei E, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980
15. Hasenclever D, Loeffler M, Diehl V for the German Hodgkin's Lymphoma Study Group: Rationale for dose escalation of first-line conventional chemotherapy in advanced Hodgkin's disease. Ann Oncol 7:95-98, 1996 (suppl 4)
16. Diehl V, Loeffler M, Pfreundschuh M, et al for the German Hodgkin's Study Group: Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease. Ann Oncol 6:901-910, 1995
17. Diehl V, Sieber M, Rüffer U, et al for the German Hodgkin's Lymphoma Study Group: BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 8:1-6, 1997
18. Tesch H, Lathan B, Rüffer U, et al: Escalation of dose-intensity for advanced stage Hodgkin's disease using the BEACOPP scheme - Studies of the German Hodgkin's Study Group (GHSG). Blood 88:637a, 1996 (abstr 2682)
19. Georgii A, Fischer R, Hübner K, et al: Classification of Hodgkin's disease biopsies by a panel of four histopathologists. Report of 1140 patients from the German national trial. Leuk Lymph 9:365-370, 1993
20. Carbone PP, Kaplan HS, Musshoff K. et al: Report of the committee on Hodgkin's disease staging. Cancer Res 31:1860-1861, 1971
21. Pocock SJ: Clinical Trials. Chichester, United Kingdom, Wiley, 1983
22. Pfreundschuh M, Rueffer U, Lathan B, et al: Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group. J Clin Oncol 12:580-586, 1994
23. Freedman LS: Tables of the number of patients required in clinical trials using the log-rank test. Stat Med 1:121-129, 1982
24. Hasenclever D, Diehl V, Armitage J, et al: A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998 (in press)
25. Loeffler ML, Brosteanu O, Hasenclever D, et al: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 16:818-829, 1998
26. Duggan D, Petroni G, Johnson J, et al: MOPP/ABV versus ABVD for advanced Hodgkin's disease - A preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc ASCO 16:12a, 1997 (abstr 43)
27. Santoro A, Bonadonna G, Valagussa P, et al: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
28. Aisenberg AC, Martino R, Nomdedeu J, et al: MOPP, ABVD or both to treat Hodgkin's disease. N Engl J Med 328:1045, 1993
29. Kreuser E-D, Felsenberg D, Behles C, et al: Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 3:S105-S110, 1992 (suppl 4)
30. Bartlett NL, Rosenberg SA, Hoppe RT, et al: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced stage Hodgkin's disease: A preliminary report. J Clin Oncol 13:1080-1088, 1995
31. Henry-Amar M, Joly F: Late complications of Hodgkin's disease. Ann Oncol 7:S115-S126, 1996 (suppl 4)
32. Tsodikov AD, Loeffler M, Yakovlev AY: A cure model with time - changing risk factor an application to the analysis of secondary leukemia. A report from the International Database on Hodgkin's Disease. J (in press)
33. van Leeuven FE, Chorus AMJ, van den Belt-Dusebout AW, et al: Leukemia risk following Hodgkin's disease: Relationship to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy and bone marrow damage. J Clin Oncol 12:1063-1073, 1994
34. Kikuta T, Shimazaki C, Hirai H, et al. Three cases of secondary acute myeloid leukemia after long-term treatment with oral etoposide. Rinsho Ketsueki (Japan) 37:1276-1282, 1996
35. Felix CA, Winick NJ, Negrini M, et al. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloin leukemia. Cancer Res 53:2954-2956, 1993
36. Whitehead J: The Design and Analysis of Sequential Clinical Trials (ed 2). Chichester, United Kingdom. Ellis Horwood, 1992
37. Whitehead J, Brunier H: PEST2.0 Operating Manual. Reading, United Kingdom, Reading University, 1989
38. Hoogstraten B, Miller AB, Staguet M, et al: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, WHO, Offset publication no. 48, 1979